CYP2D6 Hot Flashes and Tamoxifen

Options

For those of you who missed it, back in March of 2012, researchers laid to rest the common belief that patients who experience hot flashes were BETTER at metabolizing Tamoxifen.  Furthermore, CONTRARY to that belief, it was discovered that POORER metabolizers of TAmoxifen experienced MORE hot flashes.  In the same study, they found that using the CYP2D6 genetic test was of no significance either in determining how well patients' bodies metabolized Tamoxifen.  And, for those of you who were concerned because you were either a "poor" or "intermediate" metabolizer, based on the CYP2D6 test, THERE WAS NO STATISTICALLY SIGNIFICANT DATA TO SUPPORT THAT CONCLUSION, either!

Comments

  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited May 2012

    Here is The National Insititue of Cancer's Editorial on the subject:

    _____________________________________________________________________

    CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned              

    Catherine M. Kelly and                      Kathleen I. Pritchard

    + Author Affiliations

    1. <address>Affiliations of authors: Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland (CMK); Department of Medical Oncology,                           Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada (KIP)                        </address>
    1. Correspondence to:
      Kathleen I. Pritchard, MD, FRCPC, Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre,                        Toronto, ON, Canada (e-mail: kathy.pritchard@sunnybrook.ca) and Catherine M. Kelly, MD, MSc, Department of Medical Oncology, Mater Misericordiae University Hospital, 36 Eccles St,                        Dublin 7, Ireland (e-mail: Catherine.kelly@ucd.ie).                    

    He who does not know history is doomed to repeat it.

    Since 2003, there has been considerable interest and a good degree of credence given to the role of cytochrome P450 2D6 (CYP2D6)                  genotyping to predict tamoxifen benefit in adjuvant therapy (1-5). This construct was based on the fact that a variety of CYP2D6 polymorphisms lead to reduced CYP2D6 enzyme activity and hence result in lower plasma concentrations of endoxifen, a clinically                  active metabolite of tamoxifen. Tamoxifen itself is known to have a relatively weak affinity for the estrogen receptor (ER)                  and to undergo extensive primary and secondary metabolism mainly by the CYP2D6 enzyme, forming clinically active metabolites,                  which include 4-hydroxytamoxifen and endoxifen (4-hydroxytamoxifen and N-desmethyltamoxifen). These latter two metabolites                  have 30- to 100-fold greater affinity for ER compared with tamoxifen, and endoxifen has been assumed to be the most clinically                  important metabolite based on its high level in the plasma and high affinity for ER. Patients homozygous for functional CYP2D6 alleles, or heterozygous or homozygous for loss of functional CYP2D6 alleles, have been phenotypically classified as extensive, intermediate, or poor metabolizers, respectively, reflecting plasma                  concentrations of endoxifen (1,2,6). It was hypothesized that tamoxifen would be less effective in breast cancer patients with poor and intermediate metabolizer                  phenotypes and that these patients would experience fewer or less severe tamoxifen-induced hot flushes (4,7,8).              

    This theory that certain CYP2D6 genotypes and phenotypes were associated with lower endoxifen concentrations and worse breast cancer outcome was supported                  by laboratory (1,6,9), cohort (9-11), and case-control (12) studies, as well as the prototype retrospective analysis of prospectively collected samples from a North Central Cancer                  Treatment Group adjuvant breast cancer trial by Goetz et al. (4,13). A variety of subsequent articles both supported and refuted these observations (14).              

    In this issue of the Journal, two articles by Regan et al. (15) and Rae et al. (16) appear to refute the utility of CYP2D6 genotyping for predicting either tamoxifen benefit in the adjuvant setting or producing hot flushes. In these two large randomized                  studies comparing tamoxifen to an aromatase inhibitor, relatively large subsets were analyzed. In the study by Rae et al.                  (16), UK-only patients from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial were included, and in the study by                  Regan et al. (15), more than half of the patients in the Breast International Group (BIG) 1-98 Trial, for whom tumor tissues could be obtained                  were analyzed. Extracted DNA was used for genotyping and compared in multivariable analysis with endpoints of breast cancer                  recurrence (15,16) or occurrence of hot flushes (15). In neither study, was there a statistically significant association between the presence of poor or intermediate metabolizer                  phenotype and breast cancer outcome. In the study by Rae et al. (16), measurements of UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen, were also examined                  in relation to breast cancer outcome, and no association was observed. Although each of these studies has their weaknesses,                  the randomized design of the original trials, the examination of 4861 of 8010 patients randomized to receive tamoxifen or                  letrozole from BIG 1-98 (15), and 1203 of the 2145 patients randomly assigned to receive tamoxifen or anastrozole in the United Kingdom as part of the                  ATAC study (20% of the total trial) (16) provided large sample sizes, which were basically selected in an unbiased fashion. The blinded genotyping and the statistical                  analysis were also strong methodological features. The statistical power may still be insufficient to show a positive association                  between CYP2D6 activity and outcome in patients taking tamoxifen, but possibly further data from other large randomized controlled                  trials will become available.              

    However, the fact that these two studies confirm each other suggests that this matter has likely been laid to rest. Why has                  such a good hypothesis gone wrong? First, it is clear from the discussion in the study by Regan et al. (15) that endoxifen may not be the important metabolite in this setting. It seems that one of the reasons for considerable efficacy                  of tamoxifen is that several of its active metabolites actually totally saturate ER (17). Furthermore, endoxifen has a different mechanism of action than 4-hydroxytamoxifen by targeting ER-alpha for degradation                  as opposed to stabilizing it and inhibiting estradiol-mediated overexpression of amphiregulin, a ligand of epidermal growth                  factor (18). Thus, 4-hydroxytamoxifen may, in fact, be the important metabolite. Furthermore, plasma concentrations of tamoxifen and                  a primary metabolite N-desmethyltamoxifen are higher than concentrations of either endoxifen or 4-hydroxytamoxifen. Tamoxifen                  metabolites N-desmethyltamoxifen, di-desmethyltamoxifen, and 4-hydroxytamoxifen have been estimated to nearly saturate ER                  with 99.94% occupancy (17). Interestingly, the Women's Healthy Eating and Living Study (WHEL), although findings showed no relationship between endoxifen                  levels and outcome in 1370 women, did observe a poorer outcome in the 20% of women with a plasma endoxifen concentration in                  the lowest quintile compared with higher quintiles, an observation that may illustrate a minimum critical concentration threshold                  (19). This may suggest that endoxifen plays a role at low concentrations, but in general, tamoxifen is being dosed at a level                  that is more than sufficient for even poor metabolizers to derive full benefit from this drug.              

    During the last 9 years, a great industry of CYP2D6 measurement has arisen. The Food and Drug Administration (FDA) Clinical                  Pharmacology Subcommittee suggested that the tamoxifen label should be updated to include information about increased risk                  of breast cancer recurrence in CYP2D6 poor metabolizers taking tamoxifen. Although no consensus was reached regarding routine                  CYP2D6 genotype testing, many laboratories began testing for CYP2D6 allelic variants. Additional tests and charges were administered                  to patients, and therapies were presumably adjusted accordingly, all prematurely.              

    What lessons can we learn?

    • 1. We must avoid bias. The use of randomized trials prospectively designed and retrospectively analyzed is critical to assess                        the role of biomarkers such as CYP2D6.                    

    • 2. Large confirmatory studies are required for decisions regarding the use of therapeutic agents. Such studies should be required                        for the adoption of biomarkers as well.                    

    • 3. Validation of predictive biomarkers is a complicated process. The clinical importance of valid laboratory observations                        can be obscured by multiple factors. For example, when the baseline risk of recurrence is low, sometimes surgery alone is                        adequate without tamoxifen. Second, CYP2D6 phenotype would have little impact on tamoxifen benefit when the breast cancer                        is already de novo resistant to endocrine therapy. Finally, it is likely that there are many undefined drug interactions between                        tamoxifen and other medications that affect production of endoxifen and its metabolites, and ultimately treatment response.                    

    In the end, it is crucial to obtain data from randomized trials for clinical demonstration of associations between biomarkers                  and disease outcomes. To advance breast cancer therapy, laboratory observations that raise hypotheses must be at the very                  core of what we do; however, it is only after independent validation that they can begin guide clinical practice.              

    Next Section

    Funding

    None.

    Previous SectionNext Section

    Footnotes

    • The authors declare no conflict of interest. We would like to thank Prof. Lajos Pusztai, Division of Medical Oncology, University                           of Texas, MD Anderson Cancer Center (Houston, TX) for thoughtful comments regarding the complexities of biomarker validation.                       

    • © The Author 2012. Published by Oxford University Press.
    Previous Section

    References

    1. 1.
      1. Stearns V,
      2. Johnson MD,
      3. Rae JM,
      4. et al
      . Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake                                    inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758-1764.Abstract/FREE Full Text
    2. 2.
      1. Jin Y,
      2. Desta Z,
      3. Stearns V,
      4. et al
      . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.Abstract/FREE Full Text
    3. 3.
      1. Rae JM,
      2. Goetz MP,
      3. Hayes DF,
      4. et al
      . CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 2005;7(5):E6.CrossRefMedline
    4. 4.
      1. Goetz MP,
      2. Rae JM,
      3. Suman VJ,
      4. et al
      . Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. JClin Oncol. 2005;23(36):9312-9318.Abstract/FREE Full Text
    5. 5.
      1. Nowell SA,
      2. Ahn J,
      3. Rae JM,
      4. et al
      . Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast                                    cancer patients. Breast Cancer Res Treat. 2005;91(3):249-258.CrossRefMedlineWeb of Science
    6. 6.
      1. Borges S,
      2. Desta Z,
      3. Li L,
      4. et al
      . Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer                                    treatment. Clin Pharmacol Ther. 2006;80(1):61-74.CrossRefMedlineWeb of Science
    7. 7.
      1. Bonanni B,
      2. Macis D,
      3. Maisonneuve P,
      4. et al
      . Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian                                    Tamoxifen Trial. J Clin Oncol. 2006;24(22):3708-3709. author reply 9.FREE Full Text
    8. 8.
      1. Henry NL,
      2. Rae JM,
      3. Li L,
      4. et al
      . Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009;117(3):571-575.CrossRefMedlineWeb of Science
    9. 9.
      1. Xu Y,
      2. Sun Y,
      3. Yao L,
      4. et al
      . Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.Abstract/FREE Full Text
    10. 10.
      1. Kiyotani K,
      2. Mushiroda T,
      3. Sasa M,
      4. et al
      . Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99(5):995-999.CrossRefMedline
    11. 11.
      1. Bijl MJ,
      2. van Schaik RH,
      3. Lammers LA,
      4. et al
      . The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat. 2009;118(1):125-130.CrossRefMedlineWeb of Science
    12. 12.
      1. Schroth W,
      2. Antoniadou L,
      3. Fritz P,
      4. et al
      . Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.Abstract/FREE Full Text
    13. 13.
      1. Goetz MP,
      2. Knox SK,
      3. Suman VJ,
      4. et al
      . The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.CrossRefMedlineWeb of Science
    14. 14.
      1. Higgins MJ,
      2. Rae JM,
      3. Flockhart DA,
      4. Hayes DF,
      5. Stearns V
      . Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Cancer Netw. 2009;7(2):203-213.
    15. 15.
      1. Regan MM,
      2. Leyland-Jones B,
      3. Bouzyk M,
      4. et al
      . CYP2D6 genotype and tamoxifen response in postmenopausal women with estrogen-responsive early breast cancer: the Breast International                                    Group 1-98 Trial. J Natl Cancer Inst. 2012;104(6):441-451.Abstract/FREE Full Text
    16. 16.
      1. Rae JM,
      2. Drury S,
      3. Hayes DF,
      4. et al
      . CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.Abstract/FREE Full Text
    17. 17.
      1. Dowsett M,
      2. Haynes BP
      . Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003;86(3-5):255-263.CrossRefMedlineWeb of Science
    18. 18.
      1. Wu X,
      2. Hawse JR,
      3. Subramaniam M,
      4. Goetz MP,
      5. Ingle JN,
      6. Spelsberg TC
      . The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast                                    cancer cells. Cancer Res. 2009;69(5):1722-1727.Abstract/FREE Full Text
    19. 19.
      1. Madlensky L,
      2. Natarajan L,
      3. Tchu S,
      4. et al
      . Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.CrossRefMedline
  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited May 2012

    Here's one of the studies:

    __________________________________________________________________________________________________________

    J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. Epub  2012 Mar 6.

    CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

    Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

    Source

    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. mregan@jimmy.harvard.edu

    Abstract

    BACKGROUND:

    Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.

    METHODS:

    We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment. Extracted DNA was used for genotyping nine CYP2D6 single-nucleotide polymorphisms using polymerase chain reaction-based methods. Genotype combinations were used to categorize CYP2D6 metabolism phenotypes as poor, intermediate, and extensive metabolizers (PM, IM, and EM, respectively; n = 4393 patients). Associations of CYP2D6 metabolism phenotypes with breast cancer-free interval (referred to as recurrence) and treatment-induced hot flushes according to randomized endocrine treatment and previous chemotherapy were assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided.

    RESULTS:

    No association between CYP2D6 metabolism phenotypes and breast cancer-free interval was observed among patients who received tamoxifen monotherapy without previous chemotherapy (P = .35). PM or IM phenotype had a non-statistically significantly reduced risk of breast cancer recurrence compared with EM phenotype (PM or IM vs EM, HR of recurrence = 0.86, 95% CI = 0.60 to 1.24). CYP2D6 metabolism phenotype was associated with tamoxifen-induced hot flushes (P = .020). Both PM and IM phenotypes had an increased risk of tamoxifen-induced hot flushes compared with EM phenotype (PM vs EM, HR of hot flushes = 1.24, 95% CI = 0.96 to 1.59; IM vs EM, HR of hot flushes = 1.23, 95% CI = 1.05 to 1.43).

    CONCLUSIONS:

    CYP2D6 phenotypes of reduced enzyme activity were not associated with worse disease control but were associated with increased hot flushes, contrary to the hypothesis. The results of this study do not support using the presence or absence of hot flushes or the pharmacogenetic testing of CYP2D6 to determine whether to treat postmenopausal breast cancer patients with tamoxifen.

    Comment in

  • wallycat
    wallycat Member Posts: 3,227
    edited May 2012

    Sounds like this applies to Post Meno women....but these patients typically get an AI now.

    I did not link to all of your abstracts but at cursory look, no pre-meno were mentioned....?? 

  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited May 2012

    Wallycat...the researchers were specifically looking for those patients who were taking Tamoxifen. And yes, this data specifically looked at post menopausal women. The important news from this study suggests the CYP2D6 test is of no relevance to ascertaining whether or not Tamoxifen is working and that basing whether or not Tamoxifen was effective based on hot flashes did not prove to be a good predictor either.



    No PRE menopausal women were included.







  • jenrio
    jenrio Member Posts: 558
    edited May 2012

    Great thread:

    This paper on tamoxifen and endoxifen seems to indicate that only the lowest 20% percentile metabolizers may have somewhat higher risk:

    http://www.nature.com/clpt/journal/v89/n5/abs/clpt201132a.html 

    Tamoxifen has been discovered 40+ years ago.  Yet we still aren't sure how it works and why it doesn't work for certain women and fails to work long term for others.    This state of ignorance is not blissful!

    Clinical trials on endoxifen:

    http://clinicaltrials.gov/ct2/results?flds=Xc&flds=a&flds=b&flds=f&flds=j&flds=t&term=endoxifen&show_flds=Y 

  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited May 2012

    The link doesn't work. I am assuming, Jenrio, that you are referring to the Barginear study that is looking at increasing the Tamoxifen dose for poor metabolizers based on CYP2D6 results. But like you said... I think the operative word is "may."And after decades of researching and prescribing Tamoxifen and first now realizing hot flashes are NOT indicative of how well it is being metabolized, but more likely how BADLY... Hmmmmm! I am dumbstruck by this new information and ever more dumbstruck by the fact that it is not well known.

  • wallycat
    wallycat Member Posts: 3,227
    edited May 2012

    Frankly, I do not think you can extrapolate pre-meno and post meno with metabolizing.  It may be that post meno women have enough low estrogen circulating naturally, that the tamoxifen does not impact as much---which would not be the case in premenopause.

    It is a leap to presume (in my humble opinion) that pre/post meno is insignificant.  The cyp2d6 metabolization may not be an issue but it may be irrespective (or not) of the menopause status.

    I am done with my 5year antihormonals, so it is a moot point to me at this time, but if I were taking them, I would certainly care and base my decision accordingly (I was intermediate metabolizer and felt OK with the tamoxifen).

    As with every treatment we gals must endure, we make the best choice with the info we have at the time and then try not to look back and second guess ourselves.

  • voraciousreader
    voraciousreader Member Posts: 7,496
    edited May 2012

    Wally... I was premenopausal when I began this journey. On Tamoxifen and ovarian suppression. Did the CYP2D6 test and found out I was an Ultra metabolizer. Never had a single hot flash.



    I agree we make our decisions based on the best available evidence. Perhaps they will do a study of premenopausal women. Stay tuned.

  • jenrio
    jenrio Member Posts: 558
    edited May 2012

    Sorry the link above doesn't work.  let me try again:

    http://www.ncbi.nlm.nih.gov/pubmed/21430657 

    Another article on MBC patients:

    http://www.nature.com/bjc/journal/v103/n6/full/6605800a.html 

Categories